# Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

> **NCT01485861** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 298 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abiraterone
- **DRUG:** Apitolisib
- **DRUG:** Ipatasertib
- **DRUG:** Placebo
- **DRUG:** Prednisone
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT01485861
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-11
- **Primary completion:** 2015-09-01
- **Final completion:** 2022-08-31
- **Target enrollment:** 298 (ACTUAL)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01485861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01485861, "Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01485861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*